If future tests can confirm that distinct groups of UC patients harbour the toxin-producing Aeromonas strain, clinicians could classify patients by microbial subtype. In mice, antibodies that neutralised aerolysin prevented the onset of colitis, pointing to interventions focusing on the toxin as a possible strategy
